Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.

Saved in:
Bibliographic Details
Title: Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22.
Authors: Vasu S; The Ohio State University Columbus, OH United States., Denlinger N; The Ohio State University United States., Song NJ; The Ohio State University Columbus, OH United States., Elsberry D; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus, Ohio United States., Zhao Q; The Ohio State University Columbus United States., Yu L; The Ohio State University Columbus, OH United States., Bezerra ED; Mayo Clinic Rochester United States., Szuminski N; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute United States., Schneider D; Cartesian Therapeutics Frederick, Maryland United States., Dash P; Lentigen Technology (United States) Gaithersburg United States., Wirthlin L; Lentigen Technology (United States) Gaithersburg, MD United States., Epperla N; Huntsman Cancer Institute Salt Lake City, UT United States., Sawalha Y; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute United States., Woyach JA; The Ohio State University Comprehensive Cancer Center Columbus, Ohio United States., Nishat S; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute United States., Rogers KA; The Ohio State University Columbus, OH United States., Bhat SA; The Ohio State University Columbus, OH United States., Ghoneim HE; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus, Ohio United States., Behbehani GK; The Ohio State University Columbus, OH United States., Voorhees TJ; University of North Carolina at Chapel Hill Columbus, Ohio United States., Larkin K; The Ohio State University Columbus, Ohio United States., Kittai AS; The Ohio State University Mineola, NY United States., Churchill V; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute United States., George E; Nationwide Children's Hospital Columbus, Ohio United States., Lamb M; Nationwide Children's Hospital Columbus, Ohio United States., Lee DA; Nationwide Children's Hospital Columbus, Ohio United States., Chan WK; The Ohio State University Columbus, OH United States., Krull A; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute United States., Orentas RJ; Lentigen Technology (United States) Gaithersburg, MD United States., O'Donnell L; The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Columbus, OH United States., Li Z; The Ohio State University Columbus, OH United States., Alinari L; The Ohio State University Columbus, OH United States., de Lima M; The Ohio State University Columbus, OH United States.
Source: Blood cancer discovery [Blood Cancer Discov] 2026 Jul 14. Date of Electronic Publication: 2026 Jul 14.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101764786 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2643-3249 (Electronic) Linking ISSN: 26433230 NLM ISO Abbreviation: Blood Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2643-3249
DOI:10.1158/2643-3230.BCD-26-0186